l9n/ Connecticut

2017 Regular Session

Senate Bill 925

AN ACT CONCERNING THE COST OF PRESCRIPTION DRUGS AND VALUE-BASED INSURANCE DESIGN.

Did not become law. It stopped in the Senate's Insurance and Real Estate Committee on March 30, 2017. The 2017 session has ended.

What it does

The synopsis the General Assembly published with the bill.

To: (1) Require manufacturers of prescription drugs to disclose pricing information to the Insurance Commissioner; (2) require that certain insurance policies incorporate value-based insurance design; and (3) establish a task force to study methods of controlling the cost of prescription drugs.

Sponsors

Who carried the bill in each chamber, and who signed on. Each name leads to the member's page.

In the Senate

1 co-sponsor

Martin M. Looney

Its course

February 24 to March 30, 2017, on one scale. In the top row each mark is a day something happened; taller marks are busier days.

Each committee stop sits inside its chamber.

Every action11 actions on 6 days

In the SenateFeb 24 to Mar 30 · stopped34 days

Insurance and Real Estate CommitteeFeb 24 to Mar 30 · stopped34 days

Text

Each version as the General Assembly printed it.

l9n doesn't hold this bill's text yet.

What happened

In l9n's words, one line for each step. Every action as the General Assembly published it is below.

In the Senate Feb 24 – Mar 30

  1. Introduced and sent to Insurance and Real Estate Committee
  2. Heard in Insurance and Real Estate Committee
  3. A motion to recommend it failed
  4. Insurance and Real Estate Committee recommended a substitute for it
  5. Insurance and Real Estate Committee recommended it
  6. Arrived in the House of Representatives
All 11 actions, as published